Confo and Lundbeck have joined forces to push through drug discovery against a tough-to-target protein using Confo's special technology. Confo Therapeutics develops small…
Ossianix, partnered with Lundbeck, is developing shark antibodies that can help therapeutics cross the blood brain barrier. Ossianix develops shark-inspired…
Lundbeck's new CEO Kåre Schultz completely restructures the company to regain profitability. About 1/6th of the company's employees will have to leave…